WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 10.6% Following Insider Selling

WAVE Life Sciences Ltd. (NASDAQ:WVE)’s share price dropped 10.6% on Friday after an insider sold shares in the company. The company traded as low as $13.68 and last traded at $13.7350. Approximately 1,098,302 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 3,627,507 shares. The stock had previously closed at $15.36.

Specifically, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the transaction, the insider directly owned 61,867 shares of the company’s stock, valued at $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Wall Street Analyst Weigh In

WVE has been the topic of several recent analyst reports. Cantor Fitzgerald lifted their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. UBS Group set a $32.00 price target on WAVE Life Sciences in a research report on Tuesday, December 16th. Wells Fargo & Company cut their price objective on WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Thursday, February 12th. Royal Bank Of Canada upgraded WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $9.00 to $27.00 in a research note on Monday, December 8th. Finally, Leerink Partners reiterated an “outperform” rating on shares of WAVE Life Sciences in a research note on Monday, December 8th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, WAVE Life Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: INHBE obesity program progressing — Wave is advancing WVE‑007 (INHBE GalNAc‑siRNA) and is positioning it as a once‑ or twice‑yearly obesity treatment; early data show fat loss at three months similar to GLP‑1s while preserving muscle, which if confirmed could be a high‑value, low‑frequency dosing differentiator. Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
• Positive Sentiment: On track for near‑term clinical readout — Company press release reiterates INLIGHT data update expected in 1Q 2026 and highlights durable fat‑loss signals and dose‑response expectations for WVE‑007, providing a clear upcoming catalyst. Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Q4 call and transcript show mixed messaging — Management walked through a revenue beat but flagged pressures and gave operational context on the pipeline; the call transcript and highlight pieces provide detail for modeling near‑term revenue and R&D cadence. Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics — WVE reported Q4 EPS of ($0.30), missing consensus by $0.02, though revenue of $17.25M topped expectations; the company still shows large negative margins and negative ROE, underscoring continued cash burn and dilution risk. Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Insider sale by a senior executive — Chris Francis sold 33,194 shares (~$15.05 avg), cutting his ownership nearly 35%; while insider sales can be for personal reasons, markets often interpret sizable reductions by executives as a near‑term negative signal. Chris Francis insider sale

WAVE Life Sciences Price Performance

The firm has a market capitalization of $2.33 billion, a PE ratio of -11.42 and a beta of -1.78. The company’s fifty day simple moving average is $14.45 and its 200 day simple moving average is $10.81.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.02). The business had revenue of $17.25 million during the quarter. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 140.75%. On average, analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On WAVE Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GSK plc purchased a new stake in shares of WAVE Life Sciences during the fourth quarter worth $310,177,000. Adage Capital Partners GP L.L.C. raised its stake in shares of WAVE Life Sciences by 20.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after purchasing an additional 2,500,000 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of WAVE Life Sciences by 83.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after purchasing an additional 3,362,880 shares during the period. Darwin Global Management Ltd. purchased a new stake in WAVE Life Sciences during the 4th quarter worth about $125,168,000. Finally, Federated Hermes Inc. boosted its stake in WAVE Life Sciences by 26.5% in the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock worth $80,657,000 after purchasing an additional 993,827 shares during the period. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.